Multicenter Phase II Study of Second-line Cetuximab plus Folinic Acid/5-Fluorouracil/Irinotecan (FOLFIRI) in KRAS Wild-type Metastatic Colorectal Cancer: The FLIER Study

被引：5

作者：

Iwamoto, Shigeyoshi ^{[1
]}

Hazama, Shoichi ^{[2
]}

Kato, Takeshi ^{[3
]}

Miyake, Yasuhiro ^{[4
]}

Fukunaga, Mutsumi ^{[5
]}

Matsuda, Chu ^{[6
]}

Bando, Hiroyuki ^{[7
]}

Sakamoto, Junichi ^{[8
]}

Oba, Koh ^{[9
]}

Mishima, Hideyuki ^{[10
]}

机构：

[1] Kansai Med Univ, Takii Hosp, Dept Surg, Moriguchi, Osaka 5708507, Japan

[2] Yamaguchi Univ, Dept Digest Surg & Surg Oncol, Grad Sch Med, Ube, Yamaguchi 755, Japan

[3] Kansai Rosai Hosp, Dept Surg, Amagasaki, Hyogo, Japan

[4] Nishinomiya Municipal Cent Hosp, Dept Surg, Nishinomiya, Hyogo, Japan

[5] Sakai Municipal Hosp, Dept Surg, Sakai, Osaka, Japan

[6] Osaka Gen Med Ctr, Dept Surg, Osaka, Japan

[7] Ishikawa Prefectural Gen Hosp, Dept Gastrointestinal Surg, Kanazawa, Ishikawa, Japan

[8] Tokai Cent Hosp, Kakamigahara, Japan

[9] Hokkado Univ Hosp, Translat Res & Clin Trial Ctr, Sapporo, Hokkaido, Japan

[10] Aichi Med Univ Hosp, Oncol Ctr, Nagakute, Aichi, Japan

来源：

ANTICANCER RESEARCH | 2014年 / 34卷 / 04期

关键词：

Colorectal cancer; KRAS; FOLFIRI; cetuximab; Japanese; 1ST-LINE TREATMENT; RANDOMIZED-TRIAL; MUTATION STATUS; RAS MUTATIONS; OPEN-LABEL; IRINOTECAN; THERAPY; FLUOROURACIL; BEVACIZUMAB; LEUCOVORIN;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: This study was the first multicenter phase II study of cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type mCRC as a second-line treatment in Japan including BRAF and PIK3CA genotyping. Patients and Methods: Tumors of 112 pre-registered patients were genotyped for KRAS, BRAF, and PIK3CA. The primary study end-point was response rate, and secondary end-points were progression-free survival (PFS), overall survival (OS), and safety. Results: Sixty-seven patients (59.8%) were EGFR-positive and KRAS wild-type. The mean age of the enrolled patients (n=60) was 62.6 years (range=37-82 years). The response rate was 31.7% and stable disease was observed in 53.3%. No objective response was observed in patients with BRAF or PIK3CA mutations. The median PFS and OS were 7.4 and 18.2 months, respectively. Grade-3/4 adverse events were leucopenia (26.7%), neutropenia (43.3%), paronychia (10.0%), fissure (10.0%) and acne-like rash (5.0%). Conclusion: Second-line cetuximab plus FOLFIRI was effective and well-tolerated.

引用

页码：1967 / 1973

页数：7

共 50 条

[31] Combining bevacizumab and panitumumab with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as second-line treatment in patients with metastatic colorectal cancer [J].

Liang, Hong-Liang ;

Hu, Ai-Ping ;

Li, Sen-Lin ;

Liu, Ji-Yong .

MEDICAL ONCOLOGY, 2014, 31 (06)

[32] Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study [J].

Raoul, Jean-Luc ;

Van Laethem, Jean-Luc ;

Peeters, Marc ;

Brezault, Catherine ;

Husseini, Fares ;

Cals, Laurent ;

Nippgen, Johannes ;

Loos, Anja-Helena ;

Rougier, Philippe .

BMC CANCER, 2009, 9

[33] A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients [J].

C Garufi ;

E Bria ;

B Vanni ;

A M R Zappalà ;

I Sperduti ;

E Terzoli .

British Journal of Cancer, 2003, 89 :1870-1875

[34] A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients [J].

Garufi, C ;

Bria, E ;

Vanni, B ;

Zappalà, AMR ;

Sperduti, I ;

Terzoli, E .

BRITISH JOURNAL OF CANCER, 2003, 89 (10) :1870-1875

[35] The effectiveness of cetuximab and panitumumab when combined with FOLFIRI in second-line treatment of KRAS wild type metastatic colorectal cancers. Single centre experience [J].

Gursoy, Pinar ;

Cakar, Burcu ;

Almuradova, Elvina ;

Karateke, Murat ;

Doganavsargil, Basak ;

Sezak, Murat ;

Harman, Mustafa ;

Karabulut, Bulent .

JOURNAL OF CHEMOTHERAPY, 2021, 33 (03) :180-186

[36] Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer [J].

Macarulla, T. ;

Cervantes, A. ;

Tabernero, J. ;

Rosello, S. ;

Van Cutsem, E. ;

Tejpar, S. ;

Prenen, H. ;

Martinelli, E. ;

Troiani, T. ;

Laffranchi, B. ;

Jego, V. ;

von Richter, O. ;

Ciardiello, F. .

BRITISH JOURNAL OF CANCER, 2015, 112 (12) :1874-1881

[37] A multi-center randomized phase II clinical study of bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for Chinese patients with metastatic colorectal cancer [J].

Ranhua Cao ;

Shuai Zhang ;

Dedong Ma ;

Likuan Hu .

Medical Oncology, 2015, 32

[38] Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin [J].

Lang, Istvan ;

Koehne, Claus-Henning ;

Folprecht, Gunnar ;

Rougier, Philippe ;

Curran, Desmond ;

Hitre, Erika ;

Sartorius, Ute ;

Griebsch, Ingolf ;

Van Cutsem, Eric .

EUROPEAN JOURNAL OF CANCER, 2013, 49 (02) :439-448

[39] Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study [J].

Lee, Jeeyun ;

Jung, Kyung Hae ;

Park, Young Suk ;

Ahn, Joong Bae ;

Shin, Sang Jun ;

Im, Seock-Ah ;

Oh, Do Youn ;

Shin, Dong Bok ;

Kim, Tae Won ;

Lee, Namsu ;

Byun, Jae Ho ;

Hong, Yong Sang ;

Park, Joon Oh ;

Park, Se Hoon ;

Lim, Ho Yeong ;

Kang, Won Ki .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (04) :657-663

[40] Multicenter phase II study of gemcitabine and oxaliplatin (GEMOX) as second-line chemotherapy in colorectal cancer patients pretreated with 5-fluorouracil plus irinotecan [J].

Ziras, N. ;

Potamianou, A. ;

Varthalitis, I. ;

Syrigos, K. ;

Tsousis, S. ;

Boukovinas, I. ;

Tselepatiotis, E. ;

Christofillakis, C. ;

Georgoulias, V. .

ONCOLOGY, 2006, 70 (02) :106-114

← 1 2 3 4 5 →